Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K

Osimertinib.

Umberto Malapelle1, Biagio Ricciuti2, Sara Baglivo2

  • 1Department of Public Health, University of Naples Federico II, Naples, Italy.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway.

Cancer discovery·2026
Same author

PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026
Same author

Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

medRxiv : the preprint server for health sciences·2026
Same author

Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
This summary is machine-generated.

Osimertinib, a third-generation EGFR-TKI, effectively treats non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance. It shows superior efficacy as both first-line and subsequent therapy for advanced NSCLC.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced non-small cell lung cancer (NSCLC) with EGFR mutations (exons 18-21) initially responds to EGFR-TKIs.
  • Acquired resistance to first- and second-generation EGFR-TKIs emerges within a year, often due to the T790M mutation.
  • T790M mutations, found de novo or acquired, limit the efficacy of earlier EGFR-TKIs.

Purpose of the Study:

  • To review the preclinical and clinical development of osimertinib, a third-generation EGFR-TKI.
  • To discuss osimertinib's efficacy in EGFR-mutated NSCLC, including T790M-positive cases.
  • To explore osimertinib's activity in special populations and identify biomarkers for treatment sensitivity.

Main Methods:

  • Review of preclinical data and clinical trial results for osimertinib.
Keywords:
EGFR mutationEGFR-TKINon-small cell lung cancerOsimertinibT790M mutation

Related Experiment Videos

Last Updated: Feb 7, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.6K
  • Comparison of osimertinib's efficacy against platinum-based chemotherapy and earlier EGFR-TKIs.
  • Analysis of osimertinib's performance in first-line and subsequent treatment settings for advanced NSCLC.

    • Main Results:

    • Osimertinib demonstrates superior efficacy compared to platinum-based chemotherapy in T790M-positive NSCLC after prior EGFR-TKI treatment.
    • In first-line treatment of EGFR-mutated advanced NSCLC, osimertinib outperformed gefitinib or erlotinib.
    • Osimertinib acts as a new standard of care for EGFR-mutated advanced NSCLC.

    Conclusions:

    • Osimertinib is a highly effective third-generation EGFR-TKI for advanced NSCLC with specific EGFR mutations.
    • Its ability to target both activating and T790M resistance mutations offers a significant therapeutic advantage.
    • Osimertinib represents a major advancement in the treatment of EGFR-mutated NSCLC, establishing a new standard of care.